SCHEMBL11908089

SCHEMBL11908089

O=C(O)c1ccc(-c2c(F)cnc3[nH]c4cnc(Cl)cc4c23)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.42
NAPRT Q6XQN6 1/20 0.38
GPR35 Q9HC97 1/20 0.38
TOP1 P11387 1/20 0.37
MAP2K4 P45985 2/20 0.37
MAPK1 P28482 1/20 0.37
MAPK6 Q16659 1/20 0.37
AXL P30530 3/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
MAP2 P11137 1/20 0.37
SGK1 O00141 1/20 0.37
CAMKK2 Q96RR4 1/20 0.37
GABRP O00591 2/20 0.36
GABRD O14764 2/20 0.36
GABRA1 P14867 2/20 0.36
GABRB1 P18505 2/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRA5 P31644 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11907943 0.81 MKNK1 (0.46) GPR35
SCHEMBL11908677 0.79 CHEK1 (0.47)
SCHEMBL11908668 0.76 CHEK1 (0.44)
SCHEMBL11908044 0.74 PIM1 (0.37)
SCHEMBL11907789 0.74 CHEK1 (0.47)
SCHEMBL473701 0.72 GABRP (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL473714 0.70 MKNK1 (0.46)
SCHEMBL11929503 0.69 AXL (0.44) GPR35AXL
SCHEMBL11929502 0.69 KMO (0.46) GPR35
SCHEMBL1979524 0.68 MKNK1 (0.46) TTRGPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208809-A1 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-08-16 US disclosed
US-20120208809-A1 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-08-16 US disclosed
US-20120208809-A1 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-08-16 US disclosed
WO-2010109084-A2 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208809-A1 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF NPR3, CCNH, CBR3 TTR 899/4885NAPRT 3871/4885GPR35 3185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.